Just as the news of getting an international patent did, this news caused little or no action in trading. The only way the patent and this Orphan designation becomes valuable is if the drug succeeds. They are still so early in the development that the risk to invest isn't worth the potential reward as the possibly of utter failure is still very high.
They need a PR stating a huge pharma company signed on to help co-develop if they want gain attention from the "masses" of investors. Otherwise the reality is that this is a company with NO product and NO history of ever creating a product. Their script has been written and flipped three times now.. the previous 2 times left investors holding the bag while the upper management cashed checks from the capital raised.
It still makes me sick to think this company with no official full time employees was able to get several hundred thousands of dollars in Covid relief funding.
News 
Market Data 
Discover 
